Brandon Huffman: We still have a lot to learn why this largely viral-mediated cancer does not respond as well as we hope to anti-PD-1 immunotherapy
Brandon Huffman, Medical Oncologist in the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, shared an X post by James Cleary, Medical Oncologist in the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, adding:
”I am so glad to finally see this manuscript in print! This has been a work in progress since summer 2021 when I started as a senior fellow! We still have a lot to learn why this largely viral-mediated cancer does not respond as well as we hope to anti-PD-1 immunotherapy!”
Quoting James Cleary’s post:
”In our new paper, Brandon Huffman did a wonderful job examining PD1 immunotherapy in advanced Anal Cancer. Despite being an HPV driven cancer, with persistent viral antigen production, there is a wide range of responses to anti-PD1 immunotherapy. Read further.
Brandon Huffman found that many advanced Anal Cancer patients are resistant to PD1 immunotherapy and have a low number of tumor-associated CD8+PD1+ T cells. However, a small minority of anal cancer patients have long-term complete responses (>5 years) to PD1 immunotherapy.
We are profoundly grateful to the patients and co-authors who made this work possible.”
Source: Brandon Huffman/X and James Cleary/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023